

NANOTICS

To investors attending Oncology Virtual Partnering:

NaNotics, LLC is an U.S. biotechnology company headquartered in Marin, California. NaNotics is developing a new method of treating disease via injectable nanoparticles called NaNots, which deplete specific pathogenic molecules from blood. NaNotics is developing a NaNot set for treating metastatic cancer as well as a set for treating sepsis, which kills 11 million people annually.

In cancer, NaNots target tumor-generated immune-inhibitors, which all solid tumor cancers secrete to enable immune evasion. Depleting these targets from circulation induces their migration out from the tumor microenvironment, enabling immunologic response and tumor regression that safely exceeds the performance of checkpoint inhibitors (preclinical data). For treating sepsis, NaNots target key inflammatory cytokines known to drive this condition. NaNotics has completed engineering of NaNots against multiple targets, documenting efficacy in multiple disease models.

The NaNotics team invented the technology and has received six broad patents to date, with many more pending. The company has raised \$13m+ through Series A2, and has over \$2m in cash on hand. The company has both a capped and discounted bridge round open now, and is in diligence with multiple pharma venture funds for a \$60m Series B later in 2021.

We welcome you to review our online oncology deck here:

http://nanotics.com/keynote_html/NaNotics_Oncology_v19/#0

Thank you for your consideration of NaNotics. We look forward to meeting you at Oncology Virtual Partnering.

Sincerely,
Louis Hawthorne, CEO
lou@nanotics.com